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Abstract
Introduction: The objective of this study was to model the effects of transforming growth factor beta (TGF-β) and 
platelet-derived growth factor (PDGF), both present in rheumatoid arthritis (RA) synovia, on the behavior of fibroblast-
like synoviocytes (FLS) in response to pro-inflammatory cytokine (interleukin (IL)1β, tumor necrosis factor-alpha (TNFα)) 
challenge.
Methods: Gene and protein expression by fibroblast-like synoviocytes in vitro was studied by quantitative Polymerase 
Chain Reaction (qPCR), ELISA and multiplex bead cytokine assays. Intracellular signaling pathway activation was 
determined by Western blot for phospho-kinases and the use of specific inhibitors.
Results: In combination, TGF-β and PDGF (2GF) synergistically augmented TNFα- or IL1β-induced matrix 
metalloproteinase 3 (MMP3), IL6, IL8, and macrophage inflammatory protein 1 alpha (MIP1α) secretion by FLS. Other 
FLS-derived mediators remained unaffected. Individually, neither growth factor significantly potentiated TNFα or IL1β-
induced MMP3 secretion, and only slightly enhanced IL6. The effect of 2GF on TNFα-induced gene expression was 
transcriptionally mediated; blocked by imatinib mesylate; and occurred even if 2GF was added as much as four hours 
prior to TNFα. In addition, a 15-minute pulse of 2GF four hours prior to TNFα stimulation yielded a synergistic response. 
The extracellular-signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K) signaling pathways were induced 
for at least four hours by 2GF, as demonstrated by persistently upregulated levels of phospho-Akt and phospho-ERK. 
However, pharmacologic inhibitor studies demonstrated that the potentiating action of 2GF was dependent on PI3 
kinase only, and not on ERK.
Conclusions: The combination of PDGF and TGF-β dramatically potentiates FLS response to cytokines in a receptor-
mediated and PI3 kinase-dependent fashion. These data suggest that 2GF contribute to synovitis by directing synovial 
fibroblasts toward a more aggressive phenotype in response to TNFα. Therefore, inhibition of growth factor signaling 
may constitute a complementary therapeutic approach to cytokine-targeted treatments for RA.
Introduction
Expression of the regulatory peptides, platelet-derived
growth factor (PDGF) and transforming growth factor
beta (TGF-β) are increased in synovial tissue and fluid of
rheumatoid arthritis (RA) patients [1-4]. PDGF has been
implicated in RA pathogenesis, mainly through its func-
tion as a growth factor for fibroblast-like synoviocytes
(FLS) [3,5]. In contrast, the actions of TGF-β are more
complex. TGF-β plays a crucial role in maintaining
immunological tolerance through the inhibition of lym-
phocytes and macrophages [6]. On the other hand, it
recruits and activates naive monocytes [6], stimulates
proliferation [7] and induces aggrecanase synthesis [8] by
FLS. Systemic administration of TGF-β protects against
development of collagen arthritis in mice [9], whereas
direct injection of TGF-β into rat joints leads to pro-
nounced synovitis [10].
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In addition to these growth factors, chronically
inflamed RA synovia contain a multitude of inflamma-
tory mediators that may act in concert with each other. In
this context, aggravating as well as mitigating effects of
growth factors and cytokines on FLS have been demon-
s t r a t e d .  F o r  e x a m p l e ,  P D G F  w a s  r e p o r t e d  t o  e n h a n c e
IL1β-induced prostaglandin E2 production, while inhibit-
ing collagenase synthesis [11]. Also, PDGF was shown to
induce synthesis of IL8 and MIP1α, along with IL1β, by
FLS [12], and also to synergize with TNFα to stimulate
IL1β secretion, although these results are somewhat con-
fusing since FLS are not typically considered a significant
source of IL1β. On the other hand, TGF-β was earlier
shown to inhibit TNFα-induced RANTES synthesis by
FLS [13]. A systematic study of the nature of the interac-
tion among these mediators was not undertaken to date.
Hence, the interplay between PDGF, TGF-β, and cytok-
i n es  s u c h  as  T NF α  a n d  IL 1 β  o n  t h e  a ct i va t i o n  o f  F LS
remains unclear, albeit of potential significance consider-
ing the abundance of these proteins in the RA synovial
environment.
Consequently, we set out to systematically determine
the effect of PDGF and TGF-β, alone and in combination,
on inflammatory biomarker expression and secretion by
FLS. We describe significant potentiation by PDGF and
TGF-β of the production of certain cytokines, chemok-
ines, and matrix metalloproteinases (MMP) by FLS. This
synergy was mediated by tyrosine-kinase receptor activa-
tion and dependent on PI3K, both of which are receiving




Cytokines and TGF-β were obtained from R&D Labora-
tories (Minneapolis, MN, USA). Imatinib mesylate (LC
Laboratories, Woburn, MA, USA) was dissolved in water.
All other reagents, including PDGF-BB, were from Sigma
(St. Louis, MO, USA) unless otherwise noted. Stock solu-
tions in DMSO (1000×) of PD98059 and LY294002 were
kept at -80°C.
Fibroblast-like synoviocytes (FLS)
FLS were cultured from the synovial tissues of RA
patients undergoing arthroplastic surgery, as previously
described [14], after obtaining informed consent under
approval from the University of California, San Diego
Institutional Review Board, and maintained in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with
antibiotics, glutamine, and 10% fetal bovine serum. Pas-
sages 4 through 8 were used in experiments. Cells were
subjected to a two- to three-day reduced serum condition
(0.1% fetal bovine serum) prior to stimulation to mini-
mize baseline activity.
Secreted protein assays
FLS supernatants at 24 hours following stimulation were
assayed by ELISA for IL6 (eBioscience, San Diego, CA,
USA), MMP1, and MMP3 (GE Healthcare Life Sciences,
Piscataway, NJ, USA). Standard curves were constructed
by regression line fitting on log(absorbance) vs log(con-
centration). Levels of cytokines and chemokines in super-
natants were determined by Luminex multiplex analysis
(BioRad Bio-Plex assays, Hercules, CA, USA) from four-
parameter standard curve fits.
Gene expression assays
Messenger RNA for IL6, MIP1α, and MMP3 were quanti-
fied by real-time TaqMan quantitative Polymerase Chain
Reaction (qPCR), using FLS cDNA, with GAPDH used as
a housekeeper (all reagents from Applied Biosystems,
Foster City, CA, USA). Resulting threshold cycle (Ct) data
w e r e  n o r m a l i z e d  t o  s t a n d a r d  c u r v e s  c o n s t r u c t e d  f r o m
cDNA from IL1β-stimulated FLS [15], yielding cell equiv-
alents. The ratio between the specific cytokine and
GAPDH cell equivalents (relative expression units, REU)
is reported.
Western blot
FLS extracts were prepared in RIPA buffer with Complete
Protease Inhibitors (Roche Applied Science, Indianapolis,
IN, USA), denatured in sample buffer and 0.1 M
dithiotreitol, and fractioned on Invitrogen (Carlsbad, CA,
USA) NuPage 4 to 12% precast gels. Following blotting to
polyvinylidene fluoride (PVDF) membranes and blocking
with 5% dry milk, blots were probed with antibodies
against phospho- or total p38, JNK, Erk, or Akt, as well as
with secondary anti-rabbit-IgG-HRP (all Cell Signaling
Technologies, Danvers, MA, USA). GAPDH was used as
a gel loading control (antibody from Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Membranes were devel-
oped with Immun-Star WesternC ECL substrate (BioRad,
Hercules, CA, USA) and imaged on a VersaDoc imaging
system (BioRad), using QuantityOne software (Hercules,
CA, USA) for image capture and densitometry.
Statistical analysis
Data are reported as mean and standard error of the
mean (SEM). Protein secretion and gene expression data
in single time-point experiments were analyzed by one-
way ANOVA followed by Tukey-Kramer's post-hoc test
comparing all groups, or by Dunnett's post-hoc test com-
paring control to all others, as appropriate. Time course
data were analyzed by two-way ANOVA followed by con-
trast testing. Student's t-test was used to examine syner-Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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gistic effects of growth factors and cytokines. Real-time
qPCR data were log-transformed prior to analysis.
Results
Effect of PDGF-BB and TGF-β on FLS secretion of 
inflammatory mediators
Since PDGF and TGF-β are abundant in the rheumatoid
synovium, their effect on cytokine-induced inflammatory
mediator secretion by FLS was examined. TGF-β induced
only a small amount of IL6 (Figure 1a), and no effect on
IL6 (Figure 1a) or MMP3 (Figure 1b) was observed by
PDGF-BB alone. PDGF and TGF-β in combination (2GF)
induced low-level secretion of IL6, but not MMPs or
chemokines (Figures 1 and 2). The amount of IL6
secreted after 2GF stimulation was comparable to that
observed with TNFα as the stimulant (Figure 2).
Surprisingly, the two growth factors in combination
potently augmented secretion of IL6 (Figure 1a) and
M M P 3  ( F i gu r e  1 b )  i n  r es po n s e  t o  T NF α  o r  IL 1 β .  T h e
effect of 2GF was truly synergistic, in that the secretion
observed by 2GF and TNFα or IL1β in combination was
significantly higher than that obtained when adding the
values for 2GF alone and cytokine alone (Figure 1). When
PDGF-BB and TGF-β were examined individually, nei-
ther augmented TNF- or IL1β-induced MMP3 secretion,
and the effect on TNF- or IL1β-induced IL6 secretion
was smaller than that of the growth factor combination
(Figure 1). The potentiating effect of 2GF was not simply
due to a non-specific effect of cell activation, since the
secretion of some but not all mediators was affected.
TNFα-induced secretion of MMP1 and MCP1 was unal-
tered by addition of 2GF, and RANTES secretion was
inhibited, at the same time that IL8 and MIP1α secretion
was potentiated (Figure 2) along with that of IL6 and
MMP3.
The effect of 2GF was mediated through activation of
growth factor receptors, since the receptor tyrosine
kinase inhibitor, imatinib mesylate significantly reversed
Figure 1 Potentiation by PDGF alone, TGF-β alone, or their com-
bination (2GF), of (a) IL6 and (b) MMP3 secretion from FLS. FLS 
were cultured for 24 hours with TNFα (10 ng/ml) or IL1β (2 ng/ml), and/
or growth factors (10 ng/ml), and supernatants analyzed by ELISA. 
Mean & SEM, n = 3 RA FLS lines. Asterisk indicates P < 0.05 between the 
combination and the added values for TNF alone and growth factor 
alone by Students' t-test.
Figure 2 Augmentation by 2GF of FLS secretion of particular cy-
tokines, chemokines and MMPs induced by TNFα. FLS were cul-
tured for 24 hours with TNFα and growth factors as in Figure 1, and 
supernatants analyzed by ELISA (MMPs) or Luminex multiplex bead as-
say (all others). Mean & SEM, n = 3 to 6 RA FLS lines. Asterisk indicates P 
< 0.05 to TNFα alone and 2GF alone, and ampersand indicates P < 0.05 
to TNFα alone, by ANOVA/Tukey-Kramer's.Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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the potentiating effect of 2GF on TNFα-induced secre-
tion of IL6, IL8, MIP1α, and MMP3 (Figure 3). Impor-
tantly, imatinib did not alter secretion of these mediators
in response to TNFα alone.
Effect of PDGF-BB and TGF-β on the time course of FLS 
mRNA expression
In order to determine whether the effect of 2GF on FLS
protein secretion was observed at the mRNA expression
level, a time course experiment was conducted and the
expression of IL6, MIP1α, and MMP3 mRNA in FLS was
studied. TNFα caused a rapid rise in IL6 (Figure 4a) and
MIP1α (Figure 4b) mRNA expression, reaching a plateau
at one hour and maintaining significant expression until
the end of the experiment at 24 h. 2GF alone induced a
small amount of IL6 mRNA at three and eight hours, but
no MIP1α. When 2GF and TNFα was added in combina-
Figure 3 Reversal by imatinib (1 μM) of 2GF potentiation of TNFα-induced (a) IL6, (b) IL8, (c) MIP1α, and (d) MMP3 secretion. For culture con-
ditions and definitions, see legends for Figure 1 and 2. Supernatants were analyzed by ELISA or Luminex multiplex bead assay. Mean & SEM, n = 3 RA 
FLS lines. Asterisk indicates P < 0.05 to vehicle by Students' t-test.Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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tion, significantly elevated IL6 levels were observed at
three and eight hours (Figure 4a). For MIP1α (Figure 4b),
potentiation by 2GF of TNFα-induced chemokine was
only observed at three hours. Similar results were
obtained for IL8 expression (data not shown). In the case
of MMP3, TNFα alone induced a slow steady increase of
mRNA levels evident from three hours and lasting until
the end of the experiment at 24 h. The addition of 2GF in
combination with TNFα led to significantly elevated
MMP3 levels at 8, 16 and 24 h (Figure 4c). Thus, the syn-
e r g i s t i c  e f f e c t  o f  2 G F  o n  T N F α - i n d u c e d  i n f l a m m a t o r y
mediator production by FLS is evident at the transcrip-
tional level.
Effect of temporal separation of the addition of growth 
factors and TNFα to FLS
Next, the addition of 2GF and TNFα was separated in
time to determine whether the potentiating effect of 2GF
would be maintained. PDGF and TGF-β were added at
various time points in relation to TNFα, which was in
turn allowed to stimulate the FLS for 24 h before super-
natants were analyzed for secreted proteins. Under these
conditions, 2GF was able to potentiate TNFα-induced
IL6, IL8 and MMP3 secretion when added at any time
between -2 h and +2 h in relation to a TNFα addition
(Figure 5a). The extent of the potentiating effect was sim-
ilar to that observed when 2GF and TNFα were added
simultaneously (crosshatched bars). For IL6 and MMP3
secretion, potentiation by 2GF was also observed when
added as much as six hours prior to TNFα (Figure 5a).
In similar experiments studying the gene mRNA
expression at three hours following TNFα addition, 2GF
synergistically potentiated TNFα-induced IL6 expression
when added between -4 h and +2 h in relation to TNFα
addition (Figure 5b). In separate experiments, FLS could
be exposed to 2GF for as little as 15 minutes, even when
added as early as four hours before TNFα, and signifi-
cantly elevated IL6 expression could still be noted (Figure
5c). This suggests that the synergistic effect does not
require continuous exposure to the 2GF, and that it
involves signaling pathways that are maintained over the
course of several hours.
Sustained activation of Erk and Akt in FLS by growth factors
For the purpose of elucidating the relevant signaling
pathways causing the synergistic effect, FLS were treated
with TNFα, 2GF, or a combination for 15 minutes to four
hours, and cell extracts analyzed by Western blot (Figure
6a). TNFα induced a short-lived peak of phosphorylation
of p38, JNK isoforms, and ERK isoforms (Figure 6b-e) but
had a marginal effect on Akt phosphorylation (Figure 6f).
In contrast, 2GF induced a different pattern: phosphory-
lation of ERK and Akt that lasted for the four hours stud-
ied (Figure 6e-f), no phosphorylation of p38 (Figure 6b)
nor JNK-p54 (Figure 6d), and a short-lived upregulation
of phospho-JNK-p46 (Figure 6c). In combination, 2GF
and TNFα generated phospho-protein levels similar to
those induced by the mediators added separately, with
the sole exception of phospho-JNK which was signifi-
cantly higher after 15 minutes of 2GF + TNFα than after
TNF alone or 2GF alone (Figure 6c, d). At the four-hour
time point, no synergistic effect of 2GF and TNFα was
noted on any phospho-protein studied. These studies
Figure 4 Time course of 2GF-induced potentiation of (a) IL6, (b) 
MIP1α and (c) MMP3 RNA induced by TNFα. FLS were cultured for 
indicated times with TNFα and growth factors, and mRNA levels quan-
tified by real-time qPCR using GAPDH as housekeeper. Data are nor-
malized to levels with TNFα alone at 24 h. Mean & SEM, n = 3 RA FLS 
lines. Asterisk indicates P < 0.05 to TNF alone and 2GF alone by two-
way ANOVA and contrast testing on log-transformed data.Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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suggest focusing on the PI3K and MEK/ERK pathways as
potentially responsible for the synergy.
Effect of pharmacological inhibitors on 2GF potentiation of 
IL6 mRNA expression by FLS
We tested the relative contributions of the ERK and PI3K
signaling cascades to the synergistic effects of growth fac-
tors on gene expression using pharmacological inhibitors
of ERK kinase (MEK1; PD98059) and PI3K (PI3Kα,
PI3Kβ, PI3Kγ and PI3Kδ; LY294002). When 2GF and
TNFα were added simultaneously in the presence of
inhibitors, PD98059 had no effect on IL6 expression
induced by any stimuli (Figure 7a). In contrast, the PI3K
inhibitor, LY294002 had a significant effect on the IL6
expression induced by 2GF alone or TNFα alone, but in
the case of the combination the effect, although evident,
did not reach statistical significance (Figure 7a).
Since the interpretation of these results were compli-
cated by the fact that LY294002 significantly inhibited the
response to TNFα alone, 2GF were added to FLS cultures
for 15 minutes only, and then soluble 2GF was removed
by a medium change. Four hours later, TNFα was added
and allowed to stimulate the FLS for a total of three
hours, similar to the experiments shown in Figure 5c. The
potentiating effect induced by 2GF under these condi-
tions was significantly reversed if the PI3K inhibitor,
LY294002, was included prior to the 2GF pulse (Figure
7b). In this study, LY294002 had no effect on the IL6
expression induced by TNFα alone in these experiments
(Figure 7b), thus demonstrating that the effect was spe-
cific to 2GF-induced PI3K activity. Since the ERK path-
Figure 5 Synergy tolerates temporal separation of 2GF and TNFα stimulation of FLS. 2GF was added at the indicated timepoint, and left on for 
the remainder of the experiment (a-b) or removed after 15 minutes (c) (shaded bars). TNFα was added at time zero, and supernatants harvested at 
+24 h (a) or RNA isolated at +3 h (b-c). As controls, results with TNFα alone (black bar, Never) and TNF+2GF added simultaneously and left on (cross-
hatched bar) are shown. Data are normalized to levels with TNFα alone. Mean & SEM, n = 3 RA FLS lines. Asterisk indicates P < 0.05 to TNFα alone by 
ANOVA/Dunnett's on raw (a) or log-transformed (b-c) data.Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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Figure 6 Time course of phospho-protein induction by TNFα, 2GF, or a combination in FLS. (a). Representative Western blot scans. GAPDH was 
used as loading control. (b)-(f). Ratios between phospho- and total MAPK and Akt as determined by densitometry. The two ERK isoforms were ana-
lyzed together (e). Data are normalized to 2GF or TNFα alone at 15 minutes, as indicated. Mean & SEM, n = 3 RA FLS lines. Asterisk indicates P < 0.05 to 
2GF+TNFα by two-way ANOVA and contrast testing.Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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way inhibitor had no effect in this system, these results
indicate that activation of the PI3K pathway is a crucial
step for the 2GF potentiation of TNFα-induced gene
expression in FLS.
Discussion
The chronically inflamed rheumatoid synovium is a com-
plex environment with various cellular subtypes, cytok-
ines, growth factors, chemokines, proteases and
mechanical phenomena interacting with each other over
time. Animal models may provide valuable insights into
disease processes, but are limited in their ability to dem-
onstrate specific target mediated effects that correspond
to observations in RA. In addition, the typical rat and
mouse models utilized, albeit useful in many ways, do not
fully recapitulate human disease [16]. Studies of synovial
tissue ex vivo can provide a snapshot of cellular activity in
RA, and the accumulation of these observations provide
insight into disease pathogenesis. In vitro studies of iso-
lated human synovial cells can illuminate dynamic dis-
ease-specific cellular mechanisms. However, complete
recapitulation of the RA synovial complexity in vitro is
impractical if not impossible. Typical in vitro studies
involve stimulating or activating cells, blocking signaling
pathways and observing disease-relevant gene expression
or proliferative outcomes. Interestingly, such studies have
d e m o n s t r a t e d  w h a t  a p p e a r  t o  b e  u n r e s o l v e d  o p p o s i n g
effects of various mediators known to be present in the
rheumatoid synovium. In this study we attempt to incre-
mentally close the gap between cells and tissue by evalu-
ating the role of peptide mediators historically identified
as growth factors (PDGF and TGF-β) in providing a con-
text for the response of FLS to inflammatory cytokines.
The surprising and novel central finding of these stud-
ies is the significant and striking synergistic effect of a
combination of PDGF and TGF-β on cytokine-induced
FLS secretion of selected inflammatory mediators (IL6,
IL8, MIP1α and MMP3), while leaving some other media-
tors unaltered. Both PDGF and TGF-β induce prolifera-
tion of FLS [3,5,7], and cytokine-induced growth of FLS is
potentiated by PDGF [17] and TGF-β [7]. Therefore, a
potential reason for the synergistic effect of growth fac-
tors and cytokines on secretion of inflammatory media-
tors by FLS could simply be that a higher number of FLS
are present after growth factor activation. This is unlikely
to provide an explanation for our findings, however, for
two reasons. First, FLS are slow growing cells [14] and the
relatively short incubation times employed in the current
studies (3 h for mRNA, 24 h for protein secretion) make it
unlikely that a significantly higher number of FLS could
have been generated. Second, in the mRNA expression
studies, all data were normalized to GAPDH for the pur-
pose of controlling for cell numbers. Since the mRNA and
protein results essentially mirrored each other (compare
for example Figures 2 and 4, and Figures 5a and 5b), the
underlying reason for the synergy of the two growth fac-
tors along with cytokines on FLS is unlikely to be simply
an effect on cell number.
To our knowledge, this report is the first to establish a
synergy of the combined effects of PDGF and TGF-β on
cytokine-induced gene expression in FLS. The underlying
signaling mechanisms are not entirely clear. However, the
effect is receptor-mediated as demonstrated by the
reversing action of imatinib mesylate, also known as
G l e e v e c .  T h i s  c o m p o u n d  i s  a  m o d e r a t e l y  s e l e c t i v e
tyrosine kinase inhibitor that targets several classes of
receptor kinases including abl [18], c-kit [19], c-fms (the
M-CSF receptor) [20], and PDGF receptor kinases
[18,21]. In FLS, imatinib blocks PDGF-induced prolifera-
Figure 7 Involvement of PI3 kinase, but not Erk, in 2GF potentia-
tion of TNFα-induced IL6 gene expression by FLS. (a). FLS were pre-
treated with PD98059 (20 μM) or LY294002 (40 μM) 30 minutes prior to 
2GF and TNFα simultaneous addition. (b). Inhibitors were added at -4 
h 30 minutes, 2GF -4 h, and TNFα at time zero. 2GF were left on for the 
duration of the experiment (2GF cont) or left on for 15 minutes only 
(2GF pulse). RNA was isolated at three hours following TNFα stimula-
tion. Data are normalized to levels with TNFα + vehicle. Asterisk indi-
cates P < 0.05 to respective vehicle by ANOVA/Dunnett's (a) or ANOVA/
Tukey-Kramer's (b) on log-transformed data.Rosengren et al. Arthritis Research & Therapy 2010, 12:R65
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tion and phosphorylation of downstream targets of
PDGF receptor stimulation [22-25]. Due to its inhibition
of abl, imatinib also has a role in TGF-β induced signaling
and fibrogenesis in cultured fibroblasts [26,27]. Hence,
the reversal of the growth factor-induced synergy by ima-
tinib indicates involvement of specific growth factor sig-
naling pathways.
With respect to common signaling pathways in fibro-
blasts, both PDGF and TGF-β are known to activate the
PI3K [28,29] and the Ras-Raf-MEK-ERK pathways
[30,31]. Indeed, both Akt and ERK were phosphorylated
for at least four hours by 2GF treatment of FLS, making
them attractive signaling candidates. The testing of this
hypothesis was complicated by the fact that the PI3K
inhibitor used (LY294002) had significant effects on IL6
expression induced by TNFα alone, as earlier reported
[32] and similar to earlier published results where IL17
was used to induce IL6 [33]. To circumvent this problem,
we took advantage of the fact that a short pulse of 2GF,
separated in time from the TNFα stimulation, was capa-
ble of potentiating TNFα-induced IL6 expression to the
same extent as continuous incubation with 2GF without
affecting signaling in FLS stimulated with TNFα alone. In
this system, LY294002 added before 2GF and removed
prior to the addition of TNFα significantly blocked the
synergy, demonstrating a PI3K role. The ERK pathway,
however, did not appear to play a role, at least at levels
distal to MEK1. Thus, PI3K constitutes a pharmacologi-
cal target of interest for synovitis mediated by this mech-
anism. Indeed, studies antagonizing PI3K signaling have
shown promise in animal models of arthritis. Gene trans-
fer of a negative regulator of PI3K signalling, PTEN, ame-
liorates collagen arthritis [34] and in murine models of
arthritis, inhibitors of the gamma isoform PI3K have been
shown to reduce joint destruction [35]. Notably, this par-
ticular isoform was recently demonstrated to be specifi-
cally upregulated in human RA FLS [36].
These findings, in addition to demonstrating novel syn-
ergistic effects of growth factors and cytokines on FLS,
may also have clinical implications. In particular, the
effect of imatinib is of interest, since this compound is
already in clinical use for Philadelphia chromosome-posi-
tive hematological malignancies [37] as well as for gastro-
intestinal stromal tumor [38]. A few case reports exist
[39,40] of imatinib mesylate as a successful treatment for
refractory RA, with reductions in swollen joint counts
and CRP observed. In addition, a phase II study of ima-
tinib in RA has been completed (Clinicaltrials.gov identi-
fier # NCT00154336), however the results have not yet
been made publicly available. In animal models, imatinib
limits joint inflammation in mouse collagen arthritis
[23,41] and rat adjuvant arthritis [25], and reduces joint
destruction in collagen arthritis in rats [42]. Additionally,
in preliminary studies in our laboratory, imatinib limited
the arthritis induced by K/BxN serum transfer (data not
shown), a murine model in which the adaptive immune
system has been bypassed. The precise mechanism of
imatinib in RA is not known and could involve downreg-
ulation of the function of a number of cell types, as shown
in vitro: T and B lymphocytes [23,43], macrophages
[20,44], osteoclasts [42], and mast cells [23,45]. The stud-
ies described herein provide yet another potential expla-
nation for the effect of imatinib in arthritis: inhibition of a
t w o - l e g g e d  r e s p o n s e  b y  F L S ,  w h i c h  r e q u i r e  b o t h  a
cytokine and growth factors to become activated to its
fullest potential.
Conclusions
PDGF and TGF-β strongly and selectively potentiate
cytokine-induced synthesis and secretion of certain pro-
inflammatory factors by FLS, such as IL6, IL8, MIP1α,
and MMP3. The synergy was transcriptionally regulated,
and endured for at least several hours after withdrawal of
the growth factors. These data are consistent with a
model wherein PDGF and TGF-β direct the response of
synovial cells toward an RA phenotype and may partially
explain the aggressiveness of RA synovitis. Both imatinib
mesylate and a PI3K inhibitor were found to reverse this
synergy. Therefore, targeting growth factor signaling may
provide an additional approach to breaking the cycle of
sustained synovitis in RA with the goal of restoring syn-
ovial homeostasis.
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